{
  "denotations": [
    {
      "id": "T1",
      "obj": "Disease",
      "span": {
        "begin": 68,
        "end": 94
      }
    },
    {
      "id": "T2",
      "obj": "Disease",
      "span": {
        "begin": 97,
        "end": 102
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 181,
        "end": 213
      }
    },
    {
      "id": "T4",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 216,
        "end": 220
      }
    },
    {
      "id": "T7",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 326,
        "end": 330
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 181,
        "end": 248
      }
    },
    {
      "id": "T5",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 223,
        "end": 238
      }
    },
    {
      "id": "T10",
      "obj": "Chemical",
      "span": {
        "begin": 285,
        "end": 297
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "21869714_2",
  "text": "BACKGROUND : Several randomized phase III studies in advanced stage non-small cell lung cancer ( NSCLC ) confirmed the superior response rate and progression-free survival of using epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor as first-line therapy compared with chemotherapy in patients with activating EGFR mutations ."
}
